La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Arcellx Gestione

Gestione criteri di controllo 2/4

Arcellx's Il CEO è Rami Elghandour, nominato in Jan2021, e ha un mandato di 3.58 anni. la retribuzione annua totale è $ 24.96M, composta da 2.4% di stipendio e 97.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.17% delle azioni della società, per un valore di $ 6.03M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.2 anni e 4 anni.

Informazioni chiave

Rami Elghandour

Amministratore delegato

US$25.0m

Compenso totale

Percentuale dello stipendio del CEO	2.4%
Mandato del CEO	3.6yrs
Proprietà del CEO	0.2%
Durata media del management	3.2yrs
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Aug 10

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Jul 12

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Jun 01

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

May 14

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

May 12

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Nov 18

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 10

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Rami Elghandour rispetto agli utili di Arcellx?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$54m
Mar 31 2024	n/a	n/a	-US$51m
Dec 31 2023	US$25m	US$601k	-US$71m
Sep 30 2023	n/a	n/a	-US$130m
Jun 30 2023	n/a	n/a	-US$183m
Mar 31 2023	n/a	n/a	-US$190m
Dec 31 2022	US$14m	US$565k	-US$189m
Sep 30 2022	n/a	n/a	-US$170m
Jun 30 2022	n/a	n/a	-US$95m
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$23m	US$470k	-US$65m

Compensazione vs Mercato: La retribuzione totale di Rami ($USD 24.96M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.76M ).

Compensazione vs guadagni: La retribuzione di Rami è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Rami Elghandour (45 yo)

3.6yrs

Mandato

US$24,964,306

Compensazione

Mr. Rami Elghandour serves as President, Chief Executive Officer and Chairman of the Board of Directors at Arcellx, Inc. since January 2021. Mr. Elghandour joined the Arcellx, Inc. on January 22, 2021. Pre...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Rami Elghandour	Chairman of the Board	3.6yrs	US$24.96m	0.17% $ 6.2m
Michelle Gilson	Chief Financial Officer	2.3yrs	US$3.55m	0.013% $ 460.7k
Christopher Heery	Chief Medical Officer	3.3yrs	US$3.86m	0.017% $ 618.3k
Narinderjeet Singh	Chief Technical Officer	2.8yrs	Nessun dato	Nessun dato
David Tice	Chief Scientific Officer	3.1yrs	Nessun dato	Nessun dato
Myesha Lacy	Chief Investor & Communications Officer	3.6yrs	Nessun dato	Nessun dato
Maryam Abdul-Kareem	General Counsel & Chief Legal Officer	2.2yrs	Nessun dato	Nessun dato
Kate Aiken	Chief People Officer	3.6yrs	Nessun dato	Nessun dato
Neeraj Teotia	Chief Commercial Officer	3.3yrs	US$2.00m	Nessun dato
Aileen Fernandes	Chief Business Officer	2.2yrs	Nessun dato	Nessun dato

3.2yrs

Durata media

47yo

Età media

Gestione esperta: Il team dirigenziale di ACLX è considerato esperto (durata media dell'incarico 3.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Rami Elghandour	Chairman of the Board	3.6yrs	US$24.96m	0.17% $ 6.2m
David Lubner	Independent Director	4yrs	US$359.67k	0.040% $ 1.4m
Ali Behbahani	Independent Director	9.6yrs	US$355.17k	0.00079% $ 28.3k
Jill Carroll	Independent Director	6.9yrs	US$353.67k	Nessun dato
Derek Yoon	Independent Director	4.3yrs	US$347.17k	Nessun dato
Olivia Ware	Independent Director	2.3yrs	US$343.67k	Nessun dato
Kavita Patel	Independent Director	2.7yrs	US$344.67k	0% $ 0

4.0yrs

Durata media

50yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ACLX sono considerati esperti (durata media dell'incarico 4 anni).

Arcellx Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Medical Officer exercised options and sold US$320k worth of stock

Chief Medical Officer exercised options and sold US$990k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$818k worth of stock

Recent updates

Chief Medical Officer exercised options and sold US$320k worth of stock

Consensus revenue estimates increase by 21%

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Chief Medical Officer exercised options and sold US$990k worth of stock

Now 21% overvalued after recent price rise

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

New major risk - Revenue and earnings growth

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Consensus revenue estimates increase by 14%

Chief Financial Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

New major risk - Revenue and earnings growth

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Chairman of the Board recently sold US$2.4m worth of stock

New major risk - Revenue and earnings growth

Chairman of the Board notifies of intention to sell stock

Arcellx: Navigating The CAR T-Cell Revolution

Chairman of the Board recently sold US$1.6m worth of stock

Chairman of the Board notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Price target increased by 8.5% to US$65.18

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc.

Price target increased by 9.5% to US$56.55

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition

Consensus revenue estimates fall by 47%

Arcellx, Inc. Announces Partial Clinical Hold Lifted on Immagine-1 Phase 2 Clinical Program

Arcellx, Inc. Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Chairman of the Board recently sold US$115k worth of stock

Consensus EPS estimates fall by 365%

Price target increased by 12% to US$47.56

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Price target increased by 9.2% to US$43.56

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.9% to US$42.33

Chief Medical Officer exercised options and sold US$404k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arcellx, Inc. announced that it has received $100.000004 million in funding from Gilead Sciences, Inc.

Insider recently sold US$51k worth of stock

Insider recently sold US$51k worth of stock

Chief Medical Officer exercised options and sold US$231k worth of stock

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth

High number of new directors

Arcellx: The Best Is Yet To Come

Arcellx, Inc. announced delayed 10-Q filing

Arcellx GAAP EPS of -$0.88

Arcellx down 9% on day lock-up period ends

We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely

Arcellx, Inc.(NasdaqGS:ACLX) dropped from Russell 2000 Growth Index

Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy

Arcellx, Inc. Announces New Positive Clinical Data from the Ongoing Phase 1 Expansion Study of Its Novel, Autologous, CART-ddBCMA Therapy